Potential value of radiotherapy combined with immunotherapy in breast cancer brain metastases

doi:10.3760/cma.j.cn371439-20220208-00044

Abstract

Abstract:

With the increasing understanding of the unique tumor microenvironment in the brain, immunotherapy have emerged as a new and promising treatment for brain metastases. Radiotherapy and immunotherapy have a synergistic effect, and it is of great value to understand its mechanism in the treatment of breast cancer brain metastases. At present, the study of immune checkpoint inhibitors combined with radiotherapy in breast cancer brain metastases is being actively carried out, bringing new hope to patients with breast cancer brain metastases.

Key words: Breast neoplasms, Brain metastases, Immune checkpoint inhibitors, Radiotherapy

Sun Xiaolin, Zhang Zhanyu, Xu Linzong, Liu Yingchao, Li Xiaomei. Potential value of radiotherapy combined with immunotherapy in breast cancer brain metastases[J]. Journal of International Oncology, 2022, 49(4): 243-246.

References 39

[1]	Achrol AS, Rennert RC, Anders C, et al. Brain metastases[J]. Nat Rev Dis Primers, 2019, 5(1): 5. DOI: 10.1038/s41572-018-0055-y. doi: 10.1038/s41572-018-0055-y pmid: 30655533
[2]	Kuksis M, Gao Y, Tran W, et al. The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis[J]. Neuro Oncol, 2021, 23(6): 894-904. DOI: 10.1093/neuonc/noaa285. doi: 10.1093/neuonc/noaa285
[3]	中国医师协会放射肿瘤治疗医师分会. 脑转移瘤立体定向放射治疗临床指南[J]. 国际肿瘤学杂志, 2021, 48(8): 456-462. DOI: 10.3760/cma.j.cn371439-20210520-00088. doi: 10.3760/cma.j.cn371439-20210520-00088
[4]	Niesel K, Schulz M, Anthes J, et al. The immune suppressive microenvironment affects efficacy of radio-immunotherapy in brain metastasis[J]. EMBO Mol Med, 2021, 13(5): e13412. DOI: 10.15252/emmm.202013412. doi: 10.15252/emmm.202013412
[5]	A prospective, single-arm, single-center, multi-cohort phase Ⅱ clinical study of HER2-positive and triple-negative breast cancer brain metastases[EB/OL]. [2020-03-30][2021-12-02]. https://www.clinicaltrials.gov/ct2/show/NCT04303988?term=NCT04303988&draw=2&rank=1.
[6]	A phase Ⅱ study of atezolizumab in combination with pertuzumab plus high-dose trastuzumab for the treatment of central nervous system metastases in patients with Her2-positive breast cancer[EB/OL]. [2018-05-21][2021-11-02]. https://www.clinicaltrials.gov/ct2/show/NCT03417544?term=NCT03417544&draw=2&rank=1.
[7]	An Y, Jiang W, Kim BYS, et al. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control[J]. Radiother Oncol, 2017, 125(1): 80-88. DOI: 10.1016/j.radonc.2017.08.009. doi: 10.1016/j.radonc.2017.08.009
[8]	Gao C, Wang F, Suki D, et al. Effects of systemic therapy and local therapy on outcomes of 873 breast cancer patients with metastatic breast cancer to brain: MD Anderson Cancer Center experience[J]. Int J Cancer, 2021, 148(4): 961-970. DOI: 10.1002/ijc.33243. doi: 10.1002/ijc.33243
[9]	El Shafie RA, Celik A, Weber D, et al. A matched-pair analysis comparing stereotactic radiosurgery with whole-brain radiotherapy for patients with multiple brain metastases[J]. J Neurooncol, 2020, 147(3): 607-618. DOI: 10.1007/s11060-020-03447-2. doi: 10.1007/s11060-020-03447-2
[10]	Hughes RT, Masters AH, McTyre ER, et al. Initial SRS for patients with 5 to 15 brain metastases: results of a multi-institutional experience[J]. Int J Radiat Oncol Biol Phys, 2019, 104(5): 1091-1098. DOI: 10.1016/j.ijrobp.2019.03.052. doi: 10.1016/j.ijrobp.2019.03.052
[11]	Baliga S, Garg MK, Fox J, et al. Fractionated stereotactic radiation therapy for brain metastases: a systematic review with tumour control probability modelling[J]. Br J Radiol, 2017, 90(1070): 20160666. DOI: 10.1259/bjr.20160666. doi: 10.1259/bjr.20160666
[12]	A phaseⅡ pilot study of fractionated stereotactic radiotherapy (FSRT) in breast cancer patients with 1 to 10 brain metastases[EB/OL]. [2019-08-19][2021-10-02]. https://www.clinicaltrials.gov/ct2/show/record/NCT04061408?term=NCT04061408&draw=1&rank=1.
[13]	杜伟, 薛亚轲, 魏新亭, 等. 2019版AANS/CNS《成人脑转移瘤治疗的循证医学指南》解读[J]. 中华神经医学杂志, 2020, 19(2):109-112. DOI: 10.3760/cma.j.issn.1671-8925.2020.02.001. doi: 10.3760/cma.j.issn.1671-8925.2020.02.001
[14]	Gondi V, Hermann BP, Mehta MP, et al. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors[J]. Int J Radiat Oncol Biol Phys, 2013, 85(2): 348-354. DOI: 10.1016/j.ijrobp.2012.11.031. doi: 10.1016/j.ijrobp.2012.11.031
[15]	Kim JS, Kim K, Jung W, et al. New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12)[J]. Breast Cancer Res Treat, 2021, 186(2): 453-462. DOI: 10.1007/s10549-020-06043-0. doi: 10.1007/s10549-020-06043-0
[16]	Phase Ⅲ trial of post-surgical single fraction stereotactic radiosurgery (SRS) compared with fractionated SRS for resected metastatic brain disease[EB/OL]. [2019-11-11][2021-03-06]. https://www.clinicaltrials.gov/ct2/show/NCT04114981?term=NCT04114981&draw=1&rank=1.
[17]	Friebel E, Kapolou K, Unger S, et al. Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes[J]. Cell, 2020, 181(7): 1626-1642.e20. DOI: 10.1016/j.cell.2020.04.055. doi: 10.1016/j.cell.2020.04.055
[18]	Song E, Mao T, Dong H, et al. VEGF-C-driven lymphatic drai-nage enables immunosurveillance of brain tumours[J]. Nature, 2020, 577(7792): 689-694. DOI: 10.1038/s41586-019-1912-x. doi: 10.1038/s41586-019-1912-x
[19]	Taggart D, Andreou T, Scott KJ, et al. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8⁺ T cell trafficking[J]. Proc Natl Acad Sci U S A, 2018, 115(7): E1540-E1549. DOI: 10.1073/pnas.1714089115. doi: 10.1073/pnas.1714089115
[20]	Mina LA, Lim S, Bahadur SW, et al. Immunotherapy for the treatment of breast cancer: emerging new data[J]. Breast Cancer (Dove Med Press), 2019, 11: 321-328. DOI: 10.2147/BCTT.S184710. doi: 10.2147/BCTT.S184710
[21]	Camy F, Karpathiou G, Dumollard JM, et al. Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status[J]. J Immunother Cancer, 2020, 8(2): e000597. DOI: 10.1136/jitc-2020-000597. doi: 10.1136/jitc-2020-000597
[22]	Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J]. N Engl J Med, 2018, 379(22): 2108-2121. DOI: 10.1056/NEJMoa1809615. doi: 10.1056/NEJMoa1809615
[23]	Brown LC, Desai K, Wei W, et al. Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab[J]. J Immunother Cancer, 2021, 9(9): e003281. DOI: 10.1136/jitc-2021-003281. doi: 10.1136/jitc-2021-003281
[24]	Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain[J]. N Engl J Med, 2018, 379(8): 722-730. DOI: 10.1056/NEJMoa1805453. doi: 10.1056/NEJMoa1805453
[25]	Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma[J]. N Engl J Med, 2019, 381(16): 1535-1546. DOI: 10.1056/NEJMoa1910836. doi: 10.1056/NEJMoa1910836
[26]	Menon H, Chen D, Ramapriyan R, et al. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy[J]. J Immunother Cancer, 2019, 7(1): 237. DOI: 10.1186/s40425-019-0718-6. doi: 10.1186/s40425-019-0718-6 pmid: 31484556
[27]	Herter-Sprie GS, Koyama S, Korideck H, et al. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer[J]. JCI Insight, 2016, 1(9): e87415. DOI: 10.1172/jci.insight.87415. doi: 10.1172/jci.insight.87415
[28]	Golden EB, Marciscano AE, Formenti SC. Radiation therapy and the in situ vaccination approach[J]. Int J Radiat Oncol Biol Phys, 2020, 108(4): 891-898. DOI: 10.1016/j.ijrobp.2020.08.023. doi: 10.1016/j.ijrobp.2020.08.023
[29]	Liu L, Chen W, Zhang R, et al. Radiotherapy in combination with systemic therapies for brain metastases: current status and progress[J]. Cancer Biol Med, 2020, 17(4): 910-922. DOI: 10.20892/j.issn.2095-3941.2020.0109. doi: 10.20892/j.issn.2095-3941.2020.0109
[30]	Sevenich L. Turning “cold” into “hot” tumors-opportunities and challenges for radio-immunotherapy against primary and metastatic brain cancers[J]. Front Oncol, 2019, 9: 163. DOI: 10.3389/fonc.2019.00163. doi: 10.3389/fonc.2019.00163 pmid: 30941312
[31]	Chen LD, Douglass J, Kleinberg L, et al. Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2018, 100(4): 916-925. DOI: 10.1016/j.ijrobp.2017.11.041. doi: 10.1016/j.ijrobp.2017.11.041
[32]	Stokes WA, Binder DC, Jones BL, et al. Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy[J]. J Neuroimmunol, 2017, 313: 118-122. DOI: 10.1016/j.jneuroim.2017.10.006. doi: 10.1016/j.jneuroim.2017.10.006
[33]	Lehrer EJ, Peterson J, Brown PD, et al. Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: an international meta-analysis of individual patient data[J]. Radiother Oncol, 2019, 130: 104-112. DOI: 10.1016/j.radonc.2018.08.025. doi: S0167-8140(18)33465-0 pmid: 30241791
[34]	Hubbeling HG, Schapira EF, Horick NK, et al. Safety of combined PD-1 pathway inhibition and intracranial radiation therapy in non-small cell lung cancer[J]. J Thorac Oncol, 2018, 13(4): 550-558. DOI: 10.1016/j.jtho.2018.01.012. doi: S1556-0864(18)30039-X pmid: 29378267
[35]	Hadi I, Roengvoraphoj O, Bodensohn R, et al. Stereotactic radiosurgery combined with targeted/immunotherapy in patients with melanoma brain metastasis[J]. Radiat Oncol, 2020, 15(1): 37. DOI: 10.1186/s13014-020-1485-8. doi: 10.1186/s13014-020-1485-8
[36]	Shepard M, Xu Z, Donahue J, et al. Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study[J]. J Neurosurg, 2019: 1-8. DOI: 10.3171/2019.4.JNS19822. doi: 10.3171/2019.4.JNS19822
[37]	A phase Ⅱ study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis[EB/OL]. [2018-05-01][2021-09-02]. https://www.clinicaltrials.gov/ct2/show/NCT03483012?term=NCT03483012&draw=2&rank=1.
[38]	Pembrolizumab and stereotactic radiosurgery (Srs) of selected brain metastases in breast cancer patients[EB/OL]. [2018-11-15] [2021-09-22]. https://www.clinicaltrials.gov/ct2/show/NCT03449238?term=NCT03449238&draw=2&rank=1.
[39]	Phase Ⅰb study of stereotactic radiation and nivolumab in the management of metastatic breast cancer brain metastases[EB/OL]. [2019-01-30][2021-10-10]. https://www.clinicaltrials.gov/ct2/show/NCT03807765?term=NCT03807765&draw=2&rank=1.